357 filings
Page 2 of 18
8-K
ervyv
28 Dec 22
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
4:40pm
8-K
uana j579txj2
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHEREā¢ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
8-K
a1rp4c 6ymtqd3eiudp
4 Nov 22
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
6:41am
8-K
hvdgafm1w k0hwrxvd4
1 Nov 22
ImmunoGen Announces Departure of Chief Commercial Officer
9:09am
8-K
at0 hnf1eso7ix1
31 Aug 22
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
6:40am
8-K
54y zxs2nmdstbb2x5p
29 Jul 22
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
6:41am
8-K
kkm83
17 Jun 22
Departure of Directors or Certain Officers
5:07pm
8-K
9va34c
23 May 22
Regulation FD Disclosure
6:40am
8-K
s8qtza
6 May 22
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
6:41am
8-K
a1305 o1agavid2
25 Feb 22
ImmunoGen Reports Recent Progress and 2021 Financial Results
6:47am
8-K
1402j5oyz3sykh
16 Feb 22
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
4:53pm
8-K
pmjp4u71 0vp4c
10 Jan 22
Results of Operations and Financial Condition
7:30am
8-K
75ip4o03m3 tu1n21r
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
8-K
iiqcx sfawh
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
89r84
17 Nov 21
Departure of Directors or Certain Officers
4:01pm
8-K
ywtm 5a84
29 Oct 21
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
6:43am
8-K
linbgaf5qtwpg197a
23 Sep 21
Departure of Directors or Certain Officers
4:25pm
8-K
p70gq1 moptcr
12 Aug 21
Entry into a Material Definitive Agreement
10:14am
8-K
e8f79tk
30 Jul 21
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
6:36am
8-K
pzy izugrw
17 Jun 21
Departure of Directors or Certain Officers
4:13pm